> top > projects > sentences > docs > PubMed:11751483 > annotations
sentences Home  

PubMed:11751483 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-183 Sentence denotes A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
T1 0-183 Sentence denotes A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
TextSentencer_T2 184-192 Sentence denotes PURPOSE:
T2 184-192 Sentence denotes PURPOSE:
TextSentencer_T3 193-401 Sentence denotes Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC).
T3 193-401 Sentence denotes Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC).
TextSentencer_T4 402-704 Sentence denotes Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models.
T4 402-704 Sentence denotes Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models.
TextSentencer_T5 705-843 Sentence denotes In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC.
T5 705-843 Sentence denotes In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC.
TextSentencer_T6 844-851 Sentence denotes DESIGN:
T6 844-851 Sentence denotes DESIGN:
TextSentencer_T7 852-1026 Sentence denotes Twenty-six patients with HRPC were treated at seven dose levels receiving Genasense at a dose ranging from 0.6 to 5.0 mg/kg/day and mitoxantrone from 4 mg/m(2) to 12 mg/m(2).
T7 852-1026 Sentence denotes Twenty-six patients with HRPC were treated at seven dose levels receiving Genasense at a dose ranging from 0.6 to 5.0 mg/kg/day and mitoxantrone from 4 mg/m(2) to 12 mg/m(2).
TextSentencer_T8 1027-1155 Sentence denotes Genasense was administered as a 14-day i.v. continuous infusion every 28 days with mitoxantrone given as an i.v. bolus on day 8.
T8 1027-1155 Sentence denotes Genasense was administered as a 14-day i.v. continuous infusion every 28 days with mitoxantrone given as an i.v. bolus on day 8.
TextSentencer_T9 1156-1164 Sentence denotes RESULTS:
T9 1156-1164 Sentence denotes RESULTS:
TextSentencer_T10 1165-1207 Sentence denotes No dose-limiting toxicities were observed.
T10 1165-1207 Sentence denotes No dose-limiting toxicities were observed.
TextSentencer_T11 1208-1308 Sentence denotes Hematological toxicities were transient and included neutropenia, thrombocytopenia, and lymphopenia.
T11 1208-1308 Sentence denotes Hematological toxicities were transient and included neutropenia, thrombocytopenia, and lymphopenia.
TextSentencer_T12 1309-1465 Sentence denotes Nonhematological toxicities included fatigue, fever, nausea, arthralgias, myalgias, and transient elevations in serum creatinine, none of which were severe.
T12 1309-1465 Sentence denotes Nonhematological toxicities included fatigue, fever, nausea, arthralgias, myalgias, and transient elevations in serum creatinine, none of which were severe.
TextSentencer_T13 1466-1528 Sentence denotes Two patients had >50% reductions in prostate-specific antigen.
T13 1466-1528 Sentence denotes Two patients had >50% reductions in prostate-specific antigen.
TextSentencer_T14 1529-1686 Sentence denotes One patient, who received six cycles of Genasense at 1.2 mg/kg/day and a low dose (4 mg/m(2)) of mitoxantrone, also had symptomatic improvement in bone pain.
T14 1529-1686 Sentence denotes One patient, who received six cycles of Genasense at 1.2 mg/kg/day and a low dose (4 mg/m(2)) of mitoxantrone, also had symptomatic improvement in bone pain.
TextSentencer_T15 1687-1882 Sentence denotes Peripheral blood lymphocyte Bcl-2 protein expression decreased in five of five patients given Genasense at 5mg/kg/day (mean change from baseline, -12.8%; SD, 16.4%) as assessed by flow cytometry.
T15 1687-1882 Sentence denotes Peripheral blood lymphocyte Bcl-2 protein expression decreased in five of five patients given Genasense at 5mg/kg/day (mean change from baseline, -12.8%; SD, 16.4%) as assessed by flow cytometry.
TextSentencer_T16 1883-1981 Sentence denotes Serum concentrations of Genasense given at doses of 3 mg/kg/day and greater, exceeded 1 microg/ml.
T16 1883-1981 Sentence denotes Serum concentrations of Genasense given at doses of 3 mg/kg/day and greater, exceeded 1 microg/ml.
TextSentencer_T17 1982-1994 Sentence denotes CONCLUSIONS:
T17 1982-1994 Sentence denotes CONCLUSIONS:
TextSentencer_T18 1995-2194 Sentence denotes Genasense and mitoxantrone are well tolerated in combination, and mitoxantrone can be delivered at a standard dose with biologically active doses of Genasense without significant additional toxicity.
T18 1995-2194 Sentence denotes Genasense and mitoxantrone are well tolerated in combination, and mitoxantrone can be delivered at a standard dose with biologically active doses of Genasense without significant additional toxicity.
TextSentencer_T19 2195-2343 Sentence denotes This observation allays concerns about trials that combine Genasense with full doses of other cytotoxic agents seeking greater evidence of activity.
T19 2195-2343 Sentence denotes This observation allays concerns about trials that combine Genasense with full doses of other cytotoxic agents seeking greater evidence of activity.